|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | 抗血管内皮生长因子治疗湿性年龄相关性黄斑变性的效果及复发因素分析显示文摘目的评价玻璃体腔注射抗血管内皮生长因子(VEGF)药物治疗湿性年龄相关性黄斑变性(wAMD)的复发情况及其影响因素。方法采用病例对照研究,纳入2015年10月至2017年4月于空军军医大学西京医院眼科门诊行抗VEGF治疗的临床检查确诊为wAMD患者38例40眼。所有患眼均采用3+按需治疗(PRN)的康柏西普或雷珠单抗注射液治疗方案,至少随访12个月。采用国际标准对数视力表检测患眼最佳矫正视力(BCVA),同时行光相干断层扫描(OCT)检查视网膜形态学特征并测量黄斑中心凹视网膜厚度(CRT)。根据治疗后12个月随访期内是否出现复发分为复发组和非复发组,并采用多元Logistic回归分析影响复发的相关因素;观察完成负荷期治疗后1个月以及随访期末时术眼形态学和视力应答效果。结果所有术眼在治疗后12个月的随访过程中均至少出现1次视网膜积液完全吸收,其中21眼wAMD复发,占52.5%;初次积液吸收时BCVA(LogMAR)值越低,wAMD复发风险越高[OR=16.70,95%CI=1.22~100.00,P<0.05]。复发组平均接受治疗(5.8±2.3)次,明显多于未复发组的(3.5±1.4)次,差异有统计学意义(t=3.64,P<0.05);复发组和未复发组间治疗前后BCVA变化值比较差异无统计学意义(t=-1.52,P>0.05);复发组终末随访时平均BCVA(LogMAR)为0.73±0.34,较复发时的0.81±0.37明显改善,终末随访时CRT为(187.2±81.7)μm,较复发时的(234.2±74.5)μm明显降低,差异均有统计学意义(t=2.14、2.62,均P<0.05)。所有术眼中形态学应答良好者35眼,占87.5%;形态学应答不良者5眼,占12.5%,继续治疗(3.2±2.2)次后积液吸收。形态学应答良好眼在负荷期治疗后1个月时平均BCVA(LogMAR)较初次积液吸收时明显改善,差异有统计学意义(t=-2.23,P<0.05)。术眼终末随访期CRT较治疗前明显变薄,差异有统计学意义(Z=-4.62,P<0.01)。结论规范的抗VEGF药物治疗wAMD在短期内安全、有效,但仍具有较高的复发率。初次积液吸收时更好的BCVA是wAMD复发的危险因素。患者在治疗后需要长期随访以防复发。形态学应答良好患者视网膜初次积液吸收后仍需完成负荷期治疗以提高视力。 | 程子芳 王雨生 王海燕 孙董洁 朱锦婷 李曼红 | 2021 | 中华实验眼科杂志2021，39，1： | 18 |
| 2 | Effects of Huangban Bianxing One decoction combined with ranibizumab on treating exudative age-related macular degeneration显示文摘OBJECTIVE:To evaluate the clinical efficacy and safety of Chinese medicine formula Huangban Bianxing One decoction(HBOD)combined with ranibizumab for treating exudative age-related macular degeneration(AMD)patients.METHODS:Totally 75 cases with exudative AMD(75 eyes)were enrolled in this study and randomly divided into two groups to receive either HBOD with ranibizumab or only ranibizumab.Early treatment diabetic retinopathy study(ETDRS)letters for the best corrected visual acuity,center macular thickness(CMT),height of the lesion,fundus hemorrhage area,fundus fluorescein leakage area as the main outcomes and safety indexes were estimated and compared before and after treatment for 3 or 6 months.RESULTS:Comparing with the before treatment,ETDRS letter scores of both groups after treatment at month 3 obtained a greater improvement(P<0.05),but the significant improvement only existed in the HBOD+ranibizumab group at month 6(P<0.01),and better than the ranibizumab group(P<0.05).At month 3,the CMT and lesion height of both groups were significantly lower than those before treatment(P<0.01 or P<0.05)and the HBOD+ranibizumab group had a similar result at month6(P<0.01).The hemorrhage area and fluorescein leakage area of the HBOD+ranibizumab group were also significantly reduced and also smaller than those of the ranibizumab group at month 6(P<0.01 or P<0.05).During treatment,no significant adverse events relating to HBOD or ranibizumab treatment were elucidated.CONCLUSION:HBOD combined with ranibizumab can improve visual acuity and reduce hemorrhage and fluorescein leakage of patients with exudative AMD.These results also indicated that HBOD may function as an effective and safe adjuvant drug for exudative AMD. | Luo Dan Deng Tingting Yuan Wei Deng Hui Meng Huan Jin Ming | 2019 | Journal of Traditional Chinese Medicine2019，39，6： | 3 |
| 3 | 玻璃体腔注射康柏西普治疗湿性年龄相关性黄斑变性的临床观察显示文摘目的观察玻璃体腔注射康柏西普治疗湿性年龄相关性黄斑变性的短期临床疗效。方法比较35名AMD患者治疗前和治疗后1周、治疗后1个月的最佳矫正视力(BCVA)、眼压及黄斑中心视网膜厚度的变化情况。结果 35例(35只眼)AMD患者治疗前平均最佳矫正视力为(32.36±4.266)OD、眼压为(14.44±0.622)mm Hg、黄斑中心视网膜厚度为(504.2±53.20)μm。治疗后1周、治疗后1个月的平均最佳矫正视力为(43.72±4.091)OD、(40.52±4.406)OD;眼压为(15.44±1.063)mm Hg、(14.60±0.658)mm Hg;黄斑中心视网膜厚度为(238.2±31.94)μm、(289.2±42.83)μm。治疗后患者的最佳矫正视力明显提高、黄斑中心视网膜厚度明显降低(P<0.01);治疗后1周与治疗后1个月相比,差异无统计学意义(P>0.05)。治疗前与治疗后的眼压相比,差异无统计学意义(P>0.05)。所有患者在随访期间均未见明显严重不良反应。结论玻璃体腔注射康柏西普治疗湿性老年黄斑变性,短期内可显著提高视力、降低黄斑中心视网膜厚度,但是因为观察时间短、病例数少,故其长期有效性和安全性仍有待多中心临床实验的验证。 | 熊岚 李玉婷 邱亚男 杨义 | 2016 | 卫生职业教育2016，34，14： | 2 |
| 4 | Chinese medicine formula HB01 for treating exudative age-related macular degeneration: a 6 consecutive months of clinical observation study显示文摘OBJECTIVE: To evaluate the clinical efficacy of Chinese medicine formula HB01 on exudative age-related macular degeneration(AMD) patients who received HB01 for 6 months by analyzing relative indexes.METHODS: From July 2006 to August 2015, 139 eligible exudative AMD patients(183 eyes) were enrolled into this study and received aqueous extract from herbs of HB01 by oral twice a day(100 m L for once) for 6 months. The best corrected visual acuity, center macular thickness(CMT), hemorrhage area, fluorescein leakage area as the main outcomes were estimated and compared before and after treatment.RESULTS: After 3 and 6 months of treatment, visual acuity obtained a greater improvement(P < 0.01).After 1, 3 and 6 months of treatment, CMT obviously decreased(P < 0.05). After 3 and 6 months of treatment, the hemorrhage area and fluorescein leakage area also significantly narrowed(P < 0.01).During treatment, no significant adverse events relating to HB01 treatment were elucidated.CONCLUSION: On the basis of these results, HB01 could improve visual acuity, and reduce hemorrhage and fluorescein leakage of patients with exudative AMD, which may be an effective alternative and supportive treatment for exudative AMD. | Luo Dan Deng Hui Zhang Youhua Deng Tingting Yuan Wei Wang Zhijun Jin Ming | 2017 | Journal of Traditional Chinese Medicine2017，37，6： | 1 |
| 5 | Tachyphylaxis during ranibizumab treatment of exudative age-related macular degeneration显示文摘Dear Editor,We are intestigators from Turkey primarily studying exudative age-related macular degeneration(AMD).Here we present the results of our retrospective clinical study on tachyphylaxis development during the treatment of exudative AMD with ranibizumab,which,we believe,will form a basis for further prospective studies to predict the drug response in anti-vascular endothelial growth | Sibel Doguizi Sengul Ozdek Selcen Yuksel | 2015 | International Journal of Ophthalmology(English edition)2015，8，4： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员